Apathy, Parkinson Disease
Conditions
Keywords
non motor symptoms
Brief summary
The objective of this study is to describe the evolution of hypodopaminergic syndrome in patients with Parkinson's disease.
Detailed description
All patients to be included have been clinically described in the early phase of their disease, before instauration of dopaminergic treatment, in the context of a former study (Non Motor Aspects in De Novo Parkinson's Disease (Honeymoon) NCT02786667) between june 2012 and june 2016. 3 to 5 years after this study, those patients who started dopaminergic treatment will be evaluated again. The objective of this study, which takes place 3 to 5 year after the initial evaluation, is to measure the evolution of apathy and other symptoms of the hypodopaminergic syndrome. Secondary objectives are the evolution of other parameters including pain, personality and behavior. All parameters measured have been determined of each patient in the Honeymoon study.
Interventions
OTHERStarkstein scale of Apathy
The degree of apathy will be evaluated with the Starkstein scale of Apathy
Sponsors
University Hospital, Grenoble
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
33 Years to 72 Years
Healthy volunteers
No
Inclusion criteria
* patients who participated in Non Motors Aspects in De Novo Parkinson's Disease (Honeymoon) NCT02786667 * Patients under dopaminergic treatment, with stable dopaminergic treatment for at least 2 months * Patients with medical insurance * signed informed consent
Exclusion criteria
* diagnosis other than Parkinson's Disease * dementia (Mattis \<130) * patients protected by law (i.e. pregnant or parturient women)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evolution of apathy in Parkinson's disease | 1day | Evolution of apathy in Patients with Parkinson's disease under dopaminergic treatment. The degree of apathy is evaluated with the Starkstein Scale of Apathy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Apparition of hyperdopaminergic symptoms in Parkinson's disease | 1 day | Apparition of hyperdopaminergic symptoms in patients with Parkinson's disease under dopaminergic treatment, with the questionnaire for impulsive-compulsive disorders in Parkinson's disease (QUIP) and the ECMP scale. |
| Evolution of impulsivity in Parkinson's disease | 1 day | Evolution of impulsivity in patients with Parkinson's disease under dopaminergic treatment. Evaluation with a self-assessment-questionnaire (UPPS Impulsive Behavior Scale) |
| Evolution of personality in Parkinson's disease | 1 day | Evolution of personality in patients with Parkinson's disease under dopaminergic treatment with the self-assesment-questionnaire Temperament and Character Inventory (TCI). |
| Evolution of hypodopaminergia in Parkinson's disease | 1 day | Evolution of hypodopaminergic symptoms in Patients with Parkinson's disease under dopaminergic treatment. Hypodopaminergic symptoms are evaluated with different scales: ECMP (behavioral evaluation in Parkinsons's disease) for depression and anxiety, STAI (State-trait-anxiety inventory, self-assessment-questionnaire for anxiety, BDI (Beck depression inventory) for depression, PFS-16 (Piper Fatigue Sale) for fatigue. Hypodopaminergia is the expressed as the sum of its symptoms. |
| Evolution of quality of life in Parkinson's disease | 1 day | Evolution of quality of life in patients with Parkinson's disease under dopaminergic treatment with the self-assessment-questionnaire PDQ39 (Parkinson's disease questionnaire). |
| Evolution of somnolence in Parkinson's disease | 1 day | Evolution of somnolence in patients with Parkinson's disease under dopaminergic treatment with the ECMP scale. |
| Evolution of eating behavior in Parkinson's disease | 1 day | Evolution of eating behavior in patients with Parkinson's disease under dopaminergic treatment with the self-assesment-questionnaire Dutch Eating Behavior Questionnaire - DEBQ. |
| Evolution of pain in Parkinson's disease | 1 day | Evolution of pain in patients with Parkinson's disease under dopaminergic treatment with the self-assessment-questionnaire NPSI (Neuropathic Pain Symptom Inventory). |
Countries
France
Outcome results
None listed